News

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

The window shop provision in the Alcon merger agreement enabled STAAR to accept a competing acquisition proposal and terminate the Alcon merger.

Conavi leverages ophthalmic imaging technology to enhance intravascular diagnostics in cardiology.

The partnership was announced in August of this year.

OKYO Pharma advances urcosimod for neuropathic corneal pain, targeting a new clinical trial to optimize treatment and registration pathways.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research, networking opportunities, and empowering women in retina.

Discover new insights into central serous chorioretinopathy, including pathophysiology, imaging techniques, and effective treatment options for better patient outcomes.

Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.

Optos partners with Toku to integrate BioAge AI into retinal imaging devices, enhancing eye care professionals' insights into patient wellness.

Guymer discusses early intervention strategies for intermediate AMD, highlighting risk factors, and potential trial designs to prevent vision loss.

IVMED-85 is a preservative-free prescription eye drop designed to prevent myopia progression in children.

We ask leading experts in the field what eye disease they would cure and why.

Virtual Vision Health and VirtuaLens partner to enhance VR eye care tools, improving patient education and access to advanced diagnostic solutions.

Klinge Biopharma partners with Horus Pharma to commercialize the Eylea biosimilar FYB203 in Europe, enhancing market reach and therapeutic options.

A new staging system for diabetic retinopathy and macular edema is essential, integrating advanced imaging techniques for better disease management and patient outcomes.

EYP-1901 shows promising results in reducing treatment burden and improving vision in neovascular age-related macular degeneration, as revealed at EURETINA 2025.

The future of diabetic retinal imaging will be impacted by the use of widefield OCT-A technology, enhancing diagnosis and monitoring while addressing current limitations.

By combining anatomical fidelity with reproducibility, NRSS offers a novel way to train surgeons, validate clinical trials, and expand access to advanced techniques worldwide.

Lions World Vision Institute enhances corneal surgery with asymmetrical laser-cut CAIRS, offering tailored solutions for advanced keratoconus treatment.

We ask leading experts in the field what eye disease they would cure and why.

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment.

The company’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody currently in phase 1b clinical development for patients with either wAMD or DME.